Phase 2 study of two sequential three-drug combinations containing bortezomib, cyclophosphamide and dexamethasone, followed by bortezomib, thalidomide and dexamethasone as frontline therapy for multiple myeloma (Q43240420)
Jump to navigation
Jump to search
scientific article published on 16 November 2009
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Phase 2 study of two sequential three-drug combinations containing bortezomib, cyclophosphamide and dexamethasone, followed by bortezomib, thalidomide and dexamethasone as frontline therapy for multiple myeloma |
scientific article published on 16 November 2009 |
Statements
1 reference
Phase 2 study of two sequential three-drug combinations containing bortezomib, cyclophosphamide and dexamethasone, followed by bortezomib, thalidomide and dexamethasone as frontline therapy for multiple myeloma (English)
1 reference
Brian G M Durie
1 reference
William I Bensinger
1 reference
Sundar Jagannath
1 reference
Robert Vescio
1 reference
Elber Camacho
1 reference
Jeffrey Wolf
1 reference
David Irwin
1 reference
Gerardo Capo
1 reference
Marti McKinley
1 reference
Phyllis Potts
1 reference
David H Vesole
1 reference
Amitabha Mazumder
1 reference
John Crowley
1 reference
Pam Becker
1 reference
Jacqueline Hilger
1 reference
16 November 2009
1 reference
1 reference
148
1 reference
4
1 reference
562-568
1 reference
Identifiers
1 reference
1 reference